• 

  ‘The Problem of Alzheimer’s’ Makes Us Mad—In a Good Way
• 

  Pimavanserin Snag: FDA Rejects Acadia’s Dementia Psychosis Drug
• 

  As Our Oceans Change, Drugmakers Dive Deep for an Alzheimer’s Cure
• 

  How Young and Old Can Help Each Other Heal & Other March Reads
• 

  CBD for Alzheimer’s? The Cannabidiol Craze Makes Its Way Into Research
• 

  Money Management Gets Harder With Age—What to Do About It
• 

  Study: Recovering From Loneliness Even Better for the Brain Than Never Being Lonely
• 

  Amylyx “Bulletproof Vest for Neurons” Tested as Potential Alzheimer’s Therapy
• 

  ‘Supernova’: In This Moving Drama, Dementia Stars
• 

  College Football Falls Short on Concussion Prevention
• 

  Designing A Home For a Loved One With Dementia: A LiveTalk With Grant Warner
• 

  Could Arthritis Drug Olumiant Treat Alzheimer’s? A.I. Thinks So
• 

  Is Alzheimer’s Actually Three Separate Diseases?
• 

  What’s Next for Eli Lilly Alzheimer’s Drug Donanemab? Trial Enrollment Continues
• 

  Does Eli Lilly’s Alzheimer’s Drug Donanemab Work? Key New Data Released

Previous838485Next